Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Lilly Endowment Inc. sold 289,432 shares of Eli Lilly & Co (NYSE:LLY) common stock on October 31, 2025, for approximately $260.1 million. The sales occurred at prices ranging from $862.631 to $869.466 per share.
The transactions, all sales of common stock, resulted in Lilly Endowment’s remaining ownership totaling 94,231,978 shares following the transactions.
In other recent news, Eli Lilly reported impressive third-quarter earnings, significantly surpassing analyst expectations. The company achieved non-GAAP earnings per share of $7.02, well above the forecasted $5.91, and total revenue reached approximately $17.6 billion, exceeding the consensus estimate of $16.1 billion. These strong financial results prompted Eli Lilly to raise its full-year guidance. Following the earnings announcement, Jefferies raised its price target for Eli Lilly to $976, maintaining a Buy rating. Similarly, Bernstein reiterated its Outperform rating with a price target of $1,100. In addition to its financial achievements, Eli Lilly announced plans to build a $3 billion manufacturing facility in the Netherlands, aimed at expanding its production capacity for oral medicines. This new facility will incorporate advanced technologies and contribute to the global supply chain, including the manufacturing of orforglipron, which is expected to be submitted for regulatory approval for obesity by the end of the year. These developments highlight Eli Lilly’s strategic growth and expansion efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.